

16th September, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Update on USFDA inspection conducted during 3rd March, 2025 to 7th March, 2025 at Bioequivalence Facility located at Vadodara, Gujarat.

Ref.: Our intimation dated 7th March, 2025 - Completion of USFDA inspection at Alembic Pharmaceuticals Limited's Bioequivalence Facility at Vadodara.

We would like to inform the exchanges that the US Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) and has communicated the closure of inspection, which was carried out by them at the Company's Bioequivalence Facility located at Vadodara, Gujarat, during 3rd March, 2025 to 7th March, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Chirag K. Shukla
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123